SGX-listed healthcare group Singapore Paincare Holdings is set to blitzscale operations for its chain of clinics through an investment of S$1.5 million as part of a digital transformation that will cut across all its clinical operations and medical processes in Singapore and across the region.
The investment will include the implementation of artificial intelligence (AI), Internet of Medical Things (IoMT), and big data analytics in its clinics nationwide, improving the delivery and accessibility of healthcare services in line with the Ministry of Health’s Healthier SG programme.
Read also – ADB, Arnur Credit Sign Deal to Boost Financial Access for Women-Owned Small Businesses in Kazakhstan
The digitisation of its services is also expected to elevate treatment efficiency and doctor-patient relationships across its 18 clinics and centres, which currently span specialist clinics, general practitioner clinics, and traditional Chinese medicine (TCM)-cum-physiotherapy centres.
Singapore Paincare Holdings 2.0 – Advancing Patient Efficacy Through Digital Transformation As part of this digital transformation, Singapore Paincare Holdings has entered into a strategic partnership with cloud hospital and digital health technology specialists UCrest to strategise, design, and implement the adoption of these advanced technologies at scale. This will include the comprehensive integration of AI in all aspects of the business — from health services like chronic disease prevention and treatment, diagnosis, therapy, and active rehabilitation, to administrative workflows like clinic management, customer relationship management, and regulatory compliance.
Dr. Bernard Lee, Chief Executive Officer of Singapore Paincare Holdings, says: “The investment to integrate advanced technologies into our clinic services represents a pivotal move in reshaping how we deliver care. We expect to achieve improved scalability over the next 12 to 18 months, and look to continue staying ahead of industry advancements through strategic collaborations with other leaders in the digital health space, like our most recent partnership with UCrest.”
A key move towards this transformation is the newly launched iMedic digital application. Designed for better doctor-patient communication for those living with chronic health conditions, patients will be able to track daily health metrics such as blood pressure, glucose levels, and oxygen saturation within the app. Their assigned doctors will then be able to remotely monitor and provide urgent care through virtual consultations, all within a couple of taps.
“Traditional clinics are the backbone of our healthcare system, administering medical care in smaller communities in neighbourhoods. By offering remote consultations through the iMedic app, we are helping them extend this care to more Singaporeans anytime, anywhere. The app is a step in the right direction for empowering both patients in need and their healthcare practitioners, allowing clinics to deliver more timely and personalised care without the constraints of location,” adds Eg Kah Yee, Founder and Managing Director of UCrest.
Following its partnership with UCrest, Singapore Paincare Holdings is also actively working with healthcare providers across Southeast Asia and China. The group has plans to expand its presence in these regions through joint ventures or direct wholly owned setups to offer its unique technologies to new markets.
About Singapore Paincare Holdings
Singapore Paincare Holdings Limited (“Singapore Paincare”) is a healthcare group with a specialisation in treating and managing chronic and acute pain conditions across multiple medical disciplines.
We aim to be Asia’s leading one-stop pain management centre. Through our ecosystem of primary care and specialist clinics, as well as rehabilitation and wellness centres, our professional medical team of specialist doctors, general practitioners, TCM physicians and therapists support our patients on their journey from treatment to recovery and to ongoing wellness.
Singapore Paincare was incorporated in 2018 and has been listed on the Catalist board of the Singapore Exchange (SGX) since 30 July 2020.
